Century Therapeutics, Inc. Shareholders' Equity
Century Therapeutics, Inc. (IPSC) had Shareholders' Equity of $232.34 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $232.34M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $264.74M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $158.94M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $176.35M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $232.34M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $264.74M 10-Q · filed 2026-08-12 |
| 2025-12-31 | $158.94M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $176.35M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $209.90M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $240.44M 10-Q · filed 2026-08-12 |
| 2024-12-31 | $161.36M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $195.69M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $222.10M 10-Q · filed 2025-11-13 |
| 2024-03-31 | $177.88M 10-Q · filed 2025-11-13 |
| 2023-12-31 | $184.75M 10-K · filed 2026-03-12 |
| 2023-09-30 | $219.23M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $247.57M 10-Q · filed 2024-11-05 |
| 2023-03-31 | $277.18M 10-Q · filed 2024-11-05 |
| 2022-12-31 | $302.74M 10-K · filed 2025-03-19 |
| 2022-09-30 | $330.20M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $357.95M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $386.66M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $396.24M 10-K · filed 2024-03-14 |
| 2021-09-30 | $422.99M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $447.60M 10-Q · filed 2022-11-10 |
| 2021-03-31 | -$91.56M 10-Q · filed 2022-11-10 |
| 2020-12-31 | -$106.41M 10-K · filed 2023-03-16 |
| 2020-09-30 | -$129.31M 10-Q · filed 2021-11-10 |
| 2020-06-30 | -$116.35M 10-Q · filed 2021-11-10 |
| 2020-03-31 | -$101.28M 10-Q · filed 2021-11-10 |
| 2019-12-31 | -$91.86M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |